Advertisement
BEAM vs OCGN
Which Stock Would AI Choose? Beam Therapeutics (BEAM) vs. Ocugen (OCGN) Stock Comparison
Key Takeaways
- Both BEAM and OCGN are clinical-stage biotechnology companies with minimal product revenue, so their market positioning hinges heavily on pipeline milestones and regulatory catalysts.
- Beam Therapeutics carries a substantially larger market capitalization and a deeper cash position (roughly $1.2 billion) than Ocugen, extending its funding runway further into the future.
- BEAM is closer to a near-term regulatory catalyst, targeting a Biologics License Application (BLA, the formal request for U.S. marketing approval) for its sickle cell candidate by the end of 2026.
- Ocugen recently raised capital through a convertible notes offering, strengthening near-term liquidity but also introducing dilution and debt-servicing considerations.
- Both names carry elevated volatility and binary clinical risk, with consensus analyst price targets implying substantial upside from recent levels.
- For more detail on these companies, explore BEAM Major News and BEAM Today's Price Move, as well as OCGN Major News and OCGN Today's Price Move.
- To see how automated systems are currently navigating these and thousands of other tickers, explore Trending AI Robots.
Introduction
Beam Therapeutics (BEAM) and Ocugen (OCGN) are two early-stage biotechnology companies pursuing high-risk, high-reward genetic medicine pipelines. While they operate in different therapeutic areas, both are pre-revenue businesses whose stock comparisons turn on cash runway, clinical catalysts, and relative performance against the broader biotech sector. For traders and investors who follow speculative healthcare names, understanding how these two companies differ in scale, financing, and catalyst timing is central to evaluating their respective market positioning. This article examines recent developments, momentum, and the trade-offs each stock presents.
BEAM Overview and Recent Performance
Beam Therapeutics is a biotechnology company developing precision genetic medicines through a gene-editing technique known as base editing, which is designed to make precise single-letter changes to DNA without cutting the DNA strand. Its lead programs address sickle cell disease (SCD, an inherited blood disorder) and alpha-1 antitrypsin deficiency (AATD, a genetic condition affecting the liver and lungs).
In recent weeks, BEAM shares have traded in a choppy range after earlier 2026 gains, with individual clinical readouts driving sharp moves. A closely watched update on its AATD candidate BEAM-302 showed a tolerable safety profile but did not produce numerically stronger efficacy data, prompting a pullback. Management has nonetheless signaled alignment with the U.S. Food and Drug Administration (FDA) on an accelerated approval pathway for BEAM-302, and the company plans to submit a BLA for its sickle cell candidate, risto-cel, as early as year-end 2026. A cash position near $1.2 billion supports operations into mid-2029, providing meaningful financial flexibility relative to many peers.
OCGN Overview and Recent Performance
Ocugen is a biotechnology company focused on gene therapies for blindness diseases, built around a "modifier gene therapy" platform intended to treat large patient populations with a gene-agnostic approach. Its pipeline includes OCU400 for retinitis pigmentosa (RP, a rare inherited disorder causing progressive vision loss), OCU410ST for Stargardt disease, and OCU410 for geographic atrophy (GA, an advanced form of dry age-related macular degeneration).
Recent market activity has favored the downside, with OCGN shares trading near their 52-week low in recent weeks despite maintained pipeline timelines. The company reported wider quarterly losses as research and development spending increased, and it completed a convertible senior notes financing that bolstered liquidity but raised dilution concerns among investors. Management targets three BLA submissions by 2028, with a catalyst-dense period expected across 2026 and 2027. Its cash position, roughly $100 million after the financing, is expected to support operations into 2028.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-driven trading systems. While Tickeron hosts hundreds of AI trading bots that collectively trade thousands of different tickers, only the strongest performers best suited to current market conditions earn a place in this featured section. These bots span a wide range of trading styles, strategies, timeframes, performance statistics, and ticker universes, giving users a spectrum of approaches rather than a single template. For those comparing speculative names like BEAM and OCGN, observing how automated systems interpret momentum and volatility can add a quantitative layer to a fundamentally driven view. Explore Trending AI Robots to see which strategies are currently trending.
Head-to-Head Comparison
The most visible contrast between these two companies is scale and financial position. Beam Therapeutics holds a market capitalization several times larger than Ocugen's and a cash balance roughly an order of magnitude greater, giving it a longer runway before additional funding is likely needed. Ocugen, by contrast, has already leaned on convertible debt to extend its runway, a trade-off that improves liquidity while diluting existing shareholders and adding interest obligations.
Therapeutic focus also differs meaningfully. BEAM's base editing platform targets systemic genetic diseases such as sickle cell disease and AATD, whereas OCGN's modifier gene therapy platform concentrates on ophthalmology and blindness diseases. Growth drivers for BEAM center on nearer-term regulatory filings, particularly the anticipated risto-cel BLA. Ocugen's catalysts are more numerous but later-stage, with top-line data and filings concentrated in 2027 and 2028.
From a risk standpoint, both stocks are vulnerable to binary clinical outcomes, but Ocugen's smaller cash base and higher reliance on dilutive financing introduce additional capital-markets risk. Market sentiment toward BEAM has been more stable, reflecting its larger balance sheet and nearer catalysts, while OCGN has faced sharper relative performance pressure in recent weeks.
Tickeron AI Verdict
Based on observable factors such as trend consistency, balance-sheet stability, and the proximity of regulatory catalysts, Tickeron's AI would currently lean toward Beam Therapeutics (BEAM) over Ocugen (OCGN). BEAM's substantially larger cash runway, more advanced regulatory timeline, and comparatively more stable recent trading profile present a more favorable risk-reward setup on a probabilistic basis. Ocugen's pipeline breadth and analyst upside targets are notable, but its reliance on recent dilutive financing and later-stage catalyst schedule contribute to higher relative uncertainty. This assessment is probabilistic rather than definitive and may shift as new clinical data and market conditions emerge.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BEAM is a StrongBuy and OCGN is a Hold.
BEAM's RSI Oscillator recovers from overbought zone
The 10-day RSI Oscillator for BEAM moved out of overbought territory on October 30, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 instances where the indicator moved out of the overbought zone. In 21 of the 25 cases the stock moved lower in the days that followed. This puts the odds of a move down at 84%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 45 of 56 cases where BEAM's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BEAM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
BEAM broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on BEAM as a result. In 66 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
BEAM moved above its 50-day moving average on October 28, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for BEAM crossed bullishly above the 50-day moving average on November 03, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 83%.
Following a +7.42% 3-day Advance, the price is estimated to grow further. Considering data from situations where BEAM advanced for three days, in 198 of 260 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.555) is normal, around the industry mean (3.498). P/E Ratio (-38.275) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (15.314) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 47 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 53 (best 1 - 100 worst), indicating steady price growth. BEAM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BEAM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
OCGN in -9.49% downward trend, falling for three consecutive days on October 30, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where OCGN declined for three days, in 292 of 329 cases, the price declined further within the following month. The odds of a continued downward trend are 89%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
OCGN broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for OCGN entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where OCGN's RSI Indicator exited the oversold zone, 30 of 36 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on OCGN as a result. In 75 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for OCGN just turned positive on November 02, 2026. Looking at past instances where OCGN's MACD turned positive, the stock continued to rise in 45 of 55 cases over the following month. The odds of a continued upward trend are 82%.
Following a +20.67% 3-day Advance, the price is estimated to grow further. Considering data from situations where OCGN advanced for three days, in 186 of 235 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 7 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-18.946) is normal, around the industry mean (3.498). P/E Ratio (-3.558) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (70.423) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 76 (best 1 - 100 worst), indicating slightly worse than average price growth. OCGN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OCGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
BEAM | OCGN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 5 Undervalued | 7 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 92 | 100 | |
PRICE GROWTH RATING 1..100 | 53 | 76 | |
P/E GROWTH RATING 1..100 | 47 | 15 | |
SEASONALITY SCORE 1..100 | 50 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BEAM's Valuation (5) in the null industry is in the same range as OCGN (7). This means that BEAM’s stock grew similarly to OCGN’s over the last 12 months.
BEAM's Profit vs Risk Rating (100) in the null industry is in the same range as OCGN (100). This means that BEAM’s stock grew similarly to OCGN’s over the last 12 months.
BEAM's SMR Rating (92) in the null industry is in the same range as OCGN (100). This means that BEAM’s stock grew similarly to OCGN’s over the last 12 months.
BEAM's Price Growth Rating (53) in the null industry is in the same range as OCGN (76). This means that BEAM’s stock grew similarly to OCGN’s over the last 12 months.
OCGN's P/E Growth Rating (15) in the null industry is in the same range as BEAM (47). This means that OCGN’s stock grew similarly to BEAM’s over the last 12 months.
| BEAM | OCGN | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 84% | 3 days ago 83% |
| Stochastic ODDS (%) | 3 days ago 80% | 3 days ago 82% |
| Momentum ODDS (%) | 3 days ago 80% | 3 days ago 83% |
| MACD ODDS (%) | N/A | 3 days ago 82% |
| TrendWeek ODDS (%) | 3 days ago 82% | 3 days ago 78% |
| TrendMonth ODDS (%) | 3 days ago 77% | 3 days ago 87% |
| Advances ODDS (%) | 5 days ago 76% | 5 days ago 79% |
| Declines ODDS (%) | 7 days ago 84% | 10 days ago 89% |
| BollingerBands ODDS (%) | 3 days ago 76% | 3 days ago 81% |
| Aroon ODDS (%) | N/A | 3 days ago 87% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BEAM’s FA Score shows that 1 FA rating(s) are green while OCGN’s FA Score has 2 green FA rating(s).
- BEAM’s FA Score: 1 green, 4 red.
- OCGN’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BEAM’s TA Score shows that 4 TA indicator(s) are bullish while OCGN’s TA Score has 4 bullish TA indicator(s).
- BEAM’s TA Score: 4 bullish, 4 bearish.
- OCGN’s TA Score: 4 bullish, 4 bearish.
Price Growth
BEAM (@Biotechnology) experienced а -3.01% price change this week, while OCGN (@Biotechnology) price change was +31.64% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -2.35%. For the same industry, the average monthly price growth was -10.88%, and the average quarterly price growth was -18.54%.
Reported Earning Dates
BEAM is expected to report earnings on Mar 02, 2027.
OCGN is expected to report earnings on Mar 10, 2027.
Industries' Descriptions
@Biotechnology (-2.35% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
OCGN and
Correlation & Price change
A.I.dvisor indicates that over the last year, OCGN has been loosely correlated with RAIN. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if OCGN jumps, then RAIN could also see price increases.
| Ticker / NAME | Correlation To OCGN | 1D Price Change % | ||
|---|---|---|---|---|
| OCGN | 100% | +13.29% | ||
| RAIN - OCGN | 53% Loosely correlated | -6.68% | ||
| ARRY - OCGN | 47% Loosely correlated | +10.47% | ||
| BEAM - OCGN | 46% Loosely correlated | +2.09% | ||
| AXON - OCGN | 46% Loosely correlated | -18.18% | ||
| EDIT - OCGN | 43% Loosely correlated | +0.78% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| TLG | 23.96 | 0.39 | +1.64% |
| Touchstone Large Company Growth ETF (TLG) | |||
| JMHI | 48.67 | 0.13 | +0.27% |
| JPMorgan High Yield Municipal ETF (JMHI) | |||
| TEUP | 8.70 | N/A | N/A |
| T-REX 2X Long TE Daily Target ETF (TEUP) | |||
| BDVG | 14.90 | -0.04 | -0.25% |
| iMGP Berkshire Dividend Growth ETF (BDVG) | |||
| FYX | 136.73 | -0.39 | -0.28% |
| First Trust Small Cap Core Alphadex Fund (FYX) | |||